Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Anästhesie Nachrichten
Erschienen in:

07.11.2024 | Originalie

Neuroprotektive und -regenerative Medikation nach schwerem Schädel-Hirn-Trauma

Sinnvolle Ergänzung der Intensivbehandlung?

verfasst von: Prim. Univ.-Prof. Dr. Helmut Trimmel, Ivan Grgac, Günther Herzer, Christian Matula

Erschienen in: Anästhesie Nachrichten | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ursächlich für ein schweres Schädel-Hirn-Trauma (sSHT) sind zum überwiegenden Teil Verkehrsunfälle bzw. Stürze. Neben der unmittelbaren Verletzung des Gehirns aggravieren sekundäre Prozesse die Schädigung oft beträchtlich. Der vorliegende Artikel beschreibt Ursachen und mögliche medikamentöse Ansätze zur Reduktion bzw. Behandlung dieses Sekundärschadens. Es wird dabei auf Medikamente Augenmerk gelegt, die in dieser Indikation zugelassen, ubiquitär verfügbar sind sowie als sicher und nebenwirkungsarm gelten.
Vorheriger Artikel Emergency Day 2024 der ÖGARI
Nächster Artikel Analgosedierung von Kindern im Kontext einer zahnärztlichen Behandlung
Literatur
1.
Wang KK, Yang Z, Tyndall JA, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018;18:165–80.PubMedPubMedCentralCrossRef
2.
Jochems D, van Rein E, Nijboer T, et al. Incidence, causes and consequences of moderate and severe traumatic brain injury as determined by Abbreviated Injury Score in the Netherlands. Sci Rep. 2021;11:19985.PubMedPubMedCentralCrossRef
3.
Lorenz LS, Doonan M. Value and cost savings from access to multi-disciplinary rehabilitation services after severe acquired brain injury. Front Public Health. 2021;9:753447.PubMedPubMedCentralCrossRef
4.
Fu TS, Jing R, McFaull SR, Cusimano MD. Health & economic burden of traumatic brain injury in the emergency department. Can J Neurol Sci J Can Des Sci Neurol. 2016;43:238–47.CrossRef
5.
Secades JJ. Role of citicoline in the management of traumatic brain injury. Pharm. 2021;14:410.
6.
Vaccari JPR, Dietrich WD, Keane RW. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J Cereb Blood Flow Metabolism. 2013;34:369–75.CrossRef
7.
Jia Y, Wang G, Guo Z, et al. Niche Cells Crosstalk In Neuroinflammation After Traumatic Brain Injury. Int J Biol Sci. 2021;17:368–78.PubMedPubMedCentralCrossRef
8.
Hall ED, Wang JA, Hill RL, et al. Newer pharmacological approaches for antioxidant neuroprotection in traumatic brain injury. Neuropharmacology. 2019;145:247–58.PubMedCrossRef
9.
10.
Kabadi SV, Faden AI. Neuroprotective strategies for traumatic brain injury: improving clinical translation. Int J Mol Sci. 2014;15:1216–36.PubMedPubMedCentralCrossRef
11.
Rosenfeld JV, Maas AI, Gruen RL, et al. Early management of severe traumatic brain injury. Lancet. 2012;380:1088–98.PubMedCrossRef
12.
Ciryam P, Gerzanich V, Simard JM. Interleukin‑6 in traumatic brain injury: a janus-faced player in damage and repair. J Neurotrauma. 2023;.
13.
Collins-Praino LE, Corrigan F. Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury? Brain Behav Immun. 2017;60:369–82.PubMedCrossRef
14.
Shohami E, Biegon A. Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury. CNS Neurol Disord Drug Targets. 2014;13:567–73.PubMedCrossRef
15.
Taş YÇ, Solaroğlu İ, Gürsoy-Özdemir Y. Spreading depolarization waves in neurological diseases: a short review about its pathophysiology and clinical relevance. Curr Neuropharmacol. 2019;17:151–64.PubMedPubMedCentralCrossRef
16.
Soldozy S, Sharifi KA, Liu L, et al. Cortical Spreading Depression in the Setting of Traumatic Brain Injury. World Neurosurg. 2020;134:50–7.PubMedCrossRef
17.
Levi-Montalcini R. Growth control of nerve cells by a protein factor and its antiserum. Science. 1964;143:105–10.PubMedCrossRef
18.
Levi-Montalcini R. Recent studies on the NGF-target cells interaction. Differentiation. 1979;13:51–3.PubMedCrossRef
19.
Singhal NS, Sun C‑H, Lee EM, Ma DK. Resilience to injury: a new approach to neuroprotection? Neurotherapeutics. 2020;17:457–74.PubMedPubMedCentralCrossRef
20.
Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: effects of Cerebrolysin. Medicinal Res Reve. 2023;.
21.
Carney N, Totten AM, Bell MJ, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2016;1.
22.
Hawryluk GWJ, Aguilera S, Cooper DJ, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intens Care Med. 2019;45:1783–94.CrossRef
23.
Trimmel H, Herzer G, Schöchl H, Voelckel WG. Intensive care treatment of traumatic brain injury in multiple trauma patients : decision making for complex pathophysiology. Der Unfallchirurg. 2017;120:739–44.PubMedCrossRef
24.
Marehbian J, Muehlschlegel S, Hwang DY, et al. Medical Management of the Severe Traumatic Brain Injury Patient. Neurocrit Care. 2017;27:430–46.PubMedPubMedCentralCrossRef
25.
Foundation BT. Surgeons AA of N, Carney NA, et al. Guidelines for the management of severe traumatic brain injury. Introduction. J Neurotrauma. 2007;24(Suppl 1):S1–2.
26.
27.
Sparshott M. Früh- und Neugeborene pflegen. Stress- und schmerzreduzierende und entwicklungsfördernde Pflege. Huber; 2000.
28.
Wohlmannstetter M. Überpflege – gibt es das auch? Med Klin – Intensiv Notfallmedizin. 2019;114:202–6.CrossRef
29.
30.
Muresanu D. Neurotrophic factors. 2003.
31.
Brazinova A, Majdan M, Leitgeb J, Trimmel H, Mauritz W. Care AWG on I of ET. Factors that may improve outcomes of early traumatic brain injury care: prospective multicenter study in Austria. Scand J Trauma Resusc Emerg Med. 2015;23:53–11.PubMedPubMedCentralCrossRef
32.
Geeraerts T, Velly L, Bouzat P, et al. Management of severe traumatic brain injury (first 24 hours). Crit Care. 2018;37:171–86.
33.
Gravesteijn BY, Sewalt CA, Lingsma HF, et al. Prehospital Management of Traumatic Brain Injury across Europe: A CENTER-TBI Study. Prehop Emerg Care. 2021;25:629–43.CrossRef
34.
Margulies S, Hicks R. Leaders CT for TBIW. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma. 2009;26:925–39.PubMedPubMedCentralCrossRef
35.
Bergold PJ. Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol. 2016;275:367–80.PubMedCrossRef
36.
Sayed IE, Zaki A, Abdelmonem S, et al. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev. 2016;41:427–38.PubMedCrossRef
37.
Li M, Huo X, Jiang Z, et al. Effect of drug therapy on nerve repair of moderate-severe traumatic brain injury: A network meta-analysis. Front Pharmacol. 2022;13:1021653.PubMedPubMedCentralCrossRef
38.
Marshall S, Ferri C, Harnett A, et al. Attention, Concentration, and Information Processing Post Acquired Brain Injury. Evidence-based Rev Moderate To Severe Acquir Brain Inj. 2022;. www.​ERABI.​ca.
39.
40.
Herzer G, Mirth C, Trimmel H, et al. Analgosedation of adult patients with elevated intracranial pressure. Wien Klin Wochenschr. 2018;130:45–53.PubMedCrossRef
41.
Godoy DA, Badenes R, Pelosi P, Robba C. Ketamine in acute phase of severe traumatic brain injury “an old drug for new uses?”. Crit Care. 2021;25:19.PubMedPubMedCentralCrossRef
42.
Pfenninger E, Himmelseher S. Neuroprotektion durch Ketamin auf zellulärer Ebene. Anaesthesist. 1997;46:S47–S54.PubMedCrossRef
43.
Carrillo LR, Garcia KA, Yalcin N, Shah M. Ketamine and its emergence in the field of neurology. Cureus. 2022;14:e27389.
44.
Telles JPM, Welling LC, Figueiredo EG, et al. Cortical spreading depolarization and ketamine: a short systematic review. Neurophysiol Clinique. 2021;51:145–51.CrossRef
45.
Tang Y, Liu Y, Hua J, et al. Esketamine is neuroprotective against traumatic brain injury through its modulation of autophagy and oxidative stress via AMPK/mTOR-dependent TFEB nuclear translocation. Exp Neurol. 2023;366:114436.PubMedCrossRef
46.
Carlson AP, Abbas M, Shuttleworth CW, et al. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J Neurosurg. 2019;130:1513–9.PubMedCrossRef
47.
Laws JC, Vance EH, Bonfield CM, et al. Acute Effects of Ketamine on Intracranial Pressure in Children With Severe Traumatic Brain Injury. Crit Care Med. 2023;51:563–72.PubMedPubMedCentralCrossRef
48.
Mazandi VM, Lang S‑S, Zhang B, et al. Co-administration of Ketamine in Pediatric Patients with Neurologic Conditions at Risk for Intracranial Hypertension. Neurocrit Care. 2023;38:242–53.PubMedCrossRef
49.
Ossola B, Schendzielorz N, Männistö PT, et al. Corrigendum to “Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia” [Neuropharmacology 61. Neuropharmacology. 2011;62(2012):1162–582.
50.
Ossola B, Schendzielorz N, Männistö PT, et al. Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology. 2011;61:574–82.PubMedPubMedCentralCrossRef
51.
Joseph T Giacino, John Whyte, Emilia Barilla et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. New Engl J Medicine. 2012;366:819–26.CrossRef
52.
Katlowitz K, Gopinath S, Navarro JC, Robertson C. HMG-coA Reductase inhibitors for traumatic brain injury. Neurotherapeutics. 2023; 1–8.
53.
Susanto M, Siahaan AMP, Aryanti C, et al. The neuroprotective effect of statin in traumatic brain injury: A systematic review. World Neurosurg. 2023;X(19):100211.CrossRef
54.
Sultan W, Sapkota A, Went TR, et al. Statins’ Effect on Cognitive Outcome After Traumatic Brain Injury. Cureus. 2021;13:e16953.PubMedPubMedCentral
55.
Cho H‑J, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 2009;31:171.PubMedCrossRef
56.
57.
Secades JJ Citicoline: pharmacological and clinical review, 2016 update. RevNeurol. 2016;63:S1–S73.
58.
Zafonte RD, Bagiella E, Hesdorffer DC, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012;308:1993–2000.PubMedCrossRef
59.
Secades JJ, Trimmel H, Salazar B, González JA. Citicoline for the management of patients with traumatic brain injury in the acute phase: a systematic review and meta-analysis. Life. 2023; 369–84.
60.
Alvarez XA, Sampedro C, García-Fantini M, et al. Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm. 2008;115:683–92. Vienna, Austria : 1996.PubMedCrossRef
61.
Iznak AF, Iznak EV, Zavadenko NN, Guzilova LS. Neurophysiological indices of CNS plasticity in the course of treatment of head trauma in adolescents. Hum Physiol. 2008;34:672–7.CrossRef
62.
Alvarez XA, Sampedro C, Hernández A, et al. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol. 2003;18:271–8.PubMedCrossRef
63.
Zhang Y, Chopp M, Lu M, et al. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabil Neural Repair. 2019;33:15–26.PubMedCrossRef
64.
Fiani B, Covarrubias C, Nikolaidis D, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurol Sci. 2021;42:1345–53.PubMedCrossRef
65.
Yang C, Qi Y, Sun Z. The Role of Sonic Hedgehog Pathway in the Development of the Central Nervous System and Aging-Related Neurodegenerative Diseases. Front Mol Biosci. 2021;8:711710.PubMedPubMedCentralCrossRef
66.
Caplan IF, Maguire-Zeiss KA. Toll-like receptor 2 signaling and current approaches for therapeutic modulation in Synucleinopathies. Front Pharmacol. 2018;9:417.PubMedPubMedCentralCrossRef
67.
Zhang C, Chopp M, Zhang L, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke: Cerebrolysin Enhances Neurogenesis. J Neurosci Res. 2010;88:3275–81.PubMedPubMedCentralCrossRef
68.
Zhang L, Chopp M, Szalad A, et al. Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke. Stroke. 2013;44:1965–72.PubMedCrossRef
69.
Teng H, Li C, Zhang ZG, et al. Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. Publish im Druck. 2021. S. 359–66.
70.
Wong GKC, Zhu XL, Poon WS. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochir Suppl. 2005;95:59–60.PubMedCrossRef
71.
Poon W, Matula C, von Wild K, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I–a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41:281–93.PubMedCrossRef
72.
Muresanu DF, Florian S, Vos PE, et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020;41:1171–81.PubMedCrossRef
73.
Vester JC, Buzoianu AD, Lee TMC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021; 1–11.
74.
Jarosz K, Kojder K, Jurczak A, et al. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. Brain Sci. 2023;13:507.PubMedPubMedCentralCrossRef
75.
Trimmel H, Majdan M, Brazinova A, et al. Citicoline in severe traumatic brain injury: indications for improved outcome : A retrospective matched pair analysis from 14 Austrian trauma centers. Wien Klin Wochenschrift. 2018;130:37–44.CrossRef
76.
Birle C, Slavoaca D, Stan AD, et al. The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury. J Med Life. 2020;13:283–8.PubMedPubMedCentralCrossRef
77.
Varadaraju DN, Ananthakishan A. Effect of cerebroprotein hydrolysate with citicoline versus citicoline alone in the initial management of head injury and its clinical outcome a prospective randomised comparative study. J Évid Based Med Heal. 2017;4:2835–7.
78.
79.
Muresanu DF, Ciurea AV, Stan H, et al. A retrospective, multi-center cohort study evaluating the severity–related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. Cns Neurol Disord Drug Targets. 2015;14:587–99.PubMedCrossRef
80.
Ghaffarpasand F, Torabi S, Pakzad F, et al. Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsych Dis Treat. 2018;15:127–35.CrossRef
81.
Trimmel H, Herzer G, Grgac I, et al. A novel pharmacological treatment concept for neuroprotection in severe traumatic brain injury–Two case reports. Clin Case Rep. 2022;10:e6626.PubMedPubMedCentralCrossRef
Metadaten
Titel
Neuroprotektive und -regenerative Medikation nach schwerem Schädel-Hirn-Trauma
Sinnvolle Ergänzung der Intensivbehandlung?
verfasst von
Prim. Univ.-Prof. Dr. Helmut Trimmel
Ivan Grgac
Günther Herzer
Christian Matula
Publikationsdatum
07.11.2024
Verlag
Springer Vienna
Erschienen in
Anästhesie Nachrichten / Ausgabe 4/2024
Print ISSN: 2617-2127
Elektronische ISSN: 2731-3972
DOI
https://doi.org/10.1007/s44179-024-00264-0

Weitere Artikel der Ausgabe 4/2024

Die eigene Praxis als attraktive Perspektive für Anästhesist:innen?

  • Editorial

Amendment zum Abschnitt „Totenbeschau nach AS“

  • Open Access
  • Originalie

Analgosedierung von Kindern im Kontext einer zahnärztlichen Behandlung

  • Originalien

Tranexamsäure perioperativ

  • Journal Club

Widerstehen wir dem Automations-Bias

  • UPDATE Österreichische Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin

pEEG-gestützte Vollnarkose und Vasopressorbedarf bei gefäßchirurgischen Patient:innen

  • Journal Club